A detailed history of Vanguard Group Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,683,126 shares of SAVA stock, worth $79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,683,126
Previous 2,356,480 13.86%
Holding current value
$79 Million
Previous $47.8 Million 30.7%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$12.35 - $26.11 $4.03 Million - $8.53 Million
326,646 Added 13.86%
2,683,126 $33.1 Million
Q1 2024

May 10, 2024

BUY
$18.44 - $26.41 $587,387 - $841,264
31,854 Added 1.37%
2,356,480 $47.8 Million
Q4 2023

Feb 14, 2024

BUY
$12.64 - $30.11 $708,598 - $1.69 Million
56,060 Added 2.47%
2,324,626 $52.3 Million
Q3 2023

Nov 14, 2023

BUY
$16.64 - $25.32 $314,612 - $478,725
18,907 Added 0.84%
2,268,566 $37.7 Million
Q2 2023

Aug 14, 2023

BUY
$21.59 - $27.88 $275,358 - $355,581
12,754 Added 0.57%
2,249,659 $55.2 Million
Q1 2023

May 15, 2023

BUY
$23.46 - $36.44 $937,930 - $1.46 Million
39,980 Added 1.82%
2,236,905 $54 Million
Q4 2022

Feb 10, 2023

BUY
$27.82 - $44.16 $2.42 Million - $3.84 Million
87,062 Added 4.13%
2,196,925 $64.9 Million
Q3 2022

Nov 14, 2022

BUY
$16.33 - $51.06 $1.01 Million - $3.17 Million
62,151 Added 3.04%
2,109,863 $88.2 Million
Q2 2022

Aug 12, 2022

BUY
$17.22 - $38.47 $1.26 Million - $2.81 Million
72,983 Added 3.7%
2,047,712 $57.6 Million
Q1 2022

May 13, 2022

SELL
$32.6 - $53.05 $2.81 Million - $4.57 Million
-86,090 Reduced 4.18%
1,974,729 $73.3 Million
Q4 2021

Feb 14, 2022

BUY
$36.77 - $90.91 $3.18 Million - $7.87 Million
86,537 Added 4.38%
2,060,819 $90.1 Million
Q3 2021

Nov 12, 2021

BUY
$41.79 - $135.3 $6.19 Million - $20 Million
148,079 Added 8.11%
1,974,282 $123 Million
Q2 2021

Aug 13, 2021

BUY
$32.15 - $89.72 $58.7 Million - $164 Million
1,826,203 New
1,826,203 $156 Million

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.18B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.